The MACRO Trial
The Macro Trial has helped define which treatments are most effective for chronic rhinosinusitis (CRS). The study showed that sinus surgery is an effective treatment for people whose CRS symptoms have not improved with standard treatments such as steroid nasal sprays and saline (salt water) rinses.
The role of SmellTaste
SmellTaste has been a key partner in the MACRO Trial, helping to ensure that the voices of people affected by chronic rhinosinusitis and smell loss were represented throughout the research. Through its Patient and Public Involvement and Engagement (PPIE) activities, SmellTaste contributed to the design, delivery and interpretation of the study. Our role is to help researchers to better understand the aspects of treatment that matter most to people living with a smell and/or taste impairment.
What was the study investigating?
The MACRO Trial is part of a long-term UK research programme investigating the best ways to treat CRS. It compared the effectiveness and role of long-term antibiotics and sinus surgery in adults with CRS both with and without polyps.
CRS is a long-term condition that causes inflammation in the nose and sinuses. Common symptoms include a blocked or runny nose, facial pain or pressure. It is one of the leading causes of smell loss in the general population.
This study has filled an important gap in our understanding of CRS treatment. Continued follow-up over the next 5 years will provide further information about the long-term benefits and effectiveness of these different treatment options.
What did the study involve?
The MACRO Trial was a randomized controlled trial (RCT) that included 514 adults across 20 NHS hospitals. Researchers compared different treatments for people with CRS whose symptoms had not improved sufficiently with steroid nasal treatments and saline (salt water) rinses.
Participants received either:
1. Endoscopic sinus surgery (ESS), a procedure to open the sinus passages;
2. A 12-week course of the antibiotic clarithromycin; OR
3. A placebo (inactive tablet)
All participants continued to receive standard nasal treatments throughout the study.
What did researchers discover?
The study found that sinus surgery was significantly more effective at improving CRS symptoms than long-term antibiotic treatment.
After six months, 97% of people who had surgery reported an improvement in their symptoms, compared with 66% of people receiving clarithromycin and 70% receiving placebo. The study found no clear evidence that clarithromycin provided additional benefit compared with placebo.
These findings provide important evidence to guide treatment decisions for people whose CRS symptoms remain troublesome despite standard nasal treatments. The researchers concluded that sinus surgery should be considered for these patients. They found that long-term treatment with macrolide antibiotics, a type of antibiotic often used for bacterial infections of the airways, ears, nose and throat, is unlikely to benefit most people and should not be used routinely. However, some carefully selected patients may still benefit from this treatment.
What did the study find about smell recovery?
For many people living with CRS, a reduced or lost sense of smell can be one of the most difficult symptoms. As part of the study, the researchers specifically measured participants’ sense of smell. They used standardised smell testing to assess changes before and after treatment.
The study found that people who had sinus surgery were more likely to experience improvements in their sense of smell than those who received placebo treatment. However, improvements varied from person to person. Only around 4 in 10 people who had surgery experienced an improvement large enough to be considered clinically meaningful.
The researchers also looked at improvements in anosmia (complete smell loss) in individuals receiving their first sinus surgery and those who had already undergone two or more sinus surgeries.
- For those having their first sinus surgery, they found that 44% (around 4 in 10 people) had anosmia before surgery. After surgery this was reduced to 18% (around 2 in 10).
- For people who had already undergone two or more sinus surgeries, the likelihood of experiencing anosmia was higher, affecting 70% (or 7 out of 10 people). After the additional sinus surgery this was reduced to 37% (around 4 in every 10 people).
This is encouraging evidence that surgery can help some people regain some of their sense of smell. However, not everyone experienced the same benefit. We also do not yet know how long these improvements last. The researchers are continuing to follow participants for five years, which should provide a clearer picture of the longer-term effects of surgery on smell recovery.
What did patients and their doctors say about the treatment?
A follow-up study within the MACRO programme interviewed 20 people who took part in the MACRO Trial and 17 healthcare professionals involved in delivering treatment. The aim was to better understand experiences of treatment and explore how the trial findings could be used in routine care.
The follow-up confirmed that many people who had sinus surgery experienced rapid improvements in their symptoms. This included a reduction in pain, being able to breathe more easily and an improved sense of smell. Several participants described improvements in their sense of smell as one of the most valuable benefits of surgery. However, as with the main study, not everyone experienced the same improvement in their sense of smell, and the benefits varied between individuals.
Surgical recovery also differed from person to person, and some individuals were more hesitant about surgical risks and recovery time when considering treatment options. The researchers concluded that treatment decisions should consider not only the clinical evidence but also people’s preferences, concerns and expectations. They emphasise the importance of clear information, realistic expectations and shared decision-making to help people choose the treatment that best meets their needs.
What happens next?
Researchers are continuing to follow participants for up to five years to understand whether the improvements seen following treatment are maintained over time.
Further research may also help us understand which people are most likely to experience improvements in their sense of smell following treatment. SmellTaste will continue to follow the research and share developments that are particularly relevant to people experiencing smell and taste problems.
Find out more
Read the MACRO Programme lay summary for a more detailed explanation of the findings.
Read the full MACRO trial results in The Lancet.
Read more about the follow-up interviews with doctors and patients in The BMJ.
